TY - JOUR
T1 - Role of FDG PET/CT in staging of recurrent ovarian cancer
AU - Son, Hongju
AU - Khan, Shahid M.
AU - Rahaman, Jamal
AU - Cameron, Katherine L.
AU - Prasad-Hayes, Monica
AU - Chuang, Linus
AU - Machac, Josef
AU - Heiba, Sherif
AU - Kostakoglu, Lale
PY - 2011/3
Y1 - 2011/3
N2 - Ovarian cancer is the fifth leading cause of cancer death among women in the United States and has a high likelihood of recurrence despite aggressive treatment strategies. Detection and exact localization of recurrent lesions are critical for guiding management and determining the proper therapeutic approach, which may prolong survival. Because of its high sensitivity and specificity compared with those of conventional techniques such as computed tomography (CT) and magnetic resonance (MR) imaging, fluorine 18 fluorodeoxyglucose positron emission tomography (PET) combined with CT is useful for detection of recurrent or residual ovarian cancer and for monitoring response to therapy. However, PET/CT may yield false-negative results in patients with small, necrotic, mucinous, cystic, or low-grade tumors. In addition, in the posttherapy setting, inflammatory and infectious processes may lead to false-positive PET/CT results. Despite these drawbacks, PET/CT is superior to CT and MR imaging for depiction of recurrent disease.
AB - Ovarian cancer is the fifth leading cause of cancer death among women in the United States and has a high likelihood of recurrence despite aggressive treatment strategies. Detection and exact localization of recurrent lesions are critical for guiding management and determining the proper therapeutic approach, which may prolong survival. Because of its high sensitivity and specificity compared with those of conventional techniques such as computed tomography (CT) and magnetic resonance (MR) imaging, fluorine 18 fluorodeoxyglucose positron emission tomography (PET) combined with CT is useful for detection of recurrent or residual ovarian cancer and for monitoring response to therapy. However, PET/CT may yield false-negative results in patients with small, necrotic, mucinous, cystic, or low-grade tumors. In addition, in the posttherapy setting, inflammatory and infectious processes may lead to false-positive PET/CT results. Despite these drawbacks, PET/CT is superior to CT and MR imaging for depiction of recurrent disease.
UR - http://www.scopus.com/inward/record.url?scp=79953804887&partnerID=8YFLogxK
U2 - 10.1148/rg.312105713
DO - 10.1148/rg.312105713
M3 - Article
C2 - 21415197
AN - SCOPUS:79953804887
SN - 0271-5333
VL - 31
SP - 569
EP - 583
JO - Radiographics
JF - Radiographics
IS - 2
ER -